Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy

Liver International

Volumn 35, Issue 11, 2015, Pages 2370-2383

  Chon, Young E ^a,b   Jin, Bora ^a   Ahn, Sang H ^a,b   Kim, Seungtaek ^a   Kim, Nam D ^c   Park, Jeon H ^a   Nam, Chung M ^a   Kim, Kyun Hwan ^d   Hong, Sun P ^e   Choi, Sung H ^a   Kim, Do Y ^a,b   Park, Jun Y ^a,b   Han, Kwang Hyub ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Daegu Gyeongbuk Medical Innovation Foundation   (South Korea)

^d Konkuk University School of Medicine   (South Korea)

^e GeneMatrix Inc   (South Korea)

Author keywords

Chronic hepatitis B; Clonal analysis; Colocation; Drug resistance; Entecavir; Hepatitis B virus; Multidrug resistance

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CLONAL EVOLUTION; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; MALE; MIDDLE AGED; MONOTHERAPY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; RESTRICTION FRAGMENT; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MUTATION; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; CLONAL EVOLUTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; VIRAL LOAD;

EID: 84945458736     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12845     Document Type: Article

References (24)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
3. Chen C, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
5. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
6. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
7. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-95.
8. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
9. Heo N, Lim Y, Lee HC, et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-54.
10. Kim SS, Cho SW, Hong SP, Cheong JY. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol 2013; 85: 55-64.
11. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44: 593-606.
12. Han KH, Hong SP, Choi SH, et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011; 16: 77-87.
13. Kim H, Han K, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10: 441-9.
14. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England) 2013; 381: 468-75.
15. Lee CH, Kim S, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130: 1144-52.
16. Lee Y, Suh DJ, Lim Y, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-91.
17. Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 2013; 33: 116-24.
18. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012; 56: S112-22.
19. Kim K, Kim ND, Seong B. Discovery and development of anti-HBV agents and their resistance. Molecules 2010; 15: 5878-908.
20. Walsh AW, Langley DR, Colonno RJ, Tenney DJ. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One 2010; 5: e9195.
21. Mukaide M, Tanaka Y, Shin-I T, et al. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. Antimicrob Agents Chemother 2010; 54: 882-9.
22. Brunelle M, Jacquard A, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
23. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
24. Kwon HC, Cheong JY, Cho SW, et al. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 2009; 24: 49-54.